Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China

International Journal of Cardiology

Volumn 182, Issue , 2015, Pages 469-475

  Wei, Yidong ^a   Guo, Huixin ^a   The, Erlinda ^a   Che, Wenliang ^a   Shen, Jianying ^a   Hou, Lei ^a   Zhao, Shuiping ^b   Ye, Ping ^c   Li, Gang ^a   Wang, Dongzhi ^a   Jie, Qiqiang ^a   Hu, Dayi ^d  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Coronary artery disease; Diabetes mellitus; Dyslipidemia; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

AGED; BLOOD; CHINA; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PROCEDURES; RISK ASSESSMENT;

AGED; CHINA; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT;

EID: 84947202868     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.01.024     Document Type: Article

References (35)

1. K.J. Williams, and I. Tabas The response-to-retention hypothesis of early atherogenesis Arterioscler. Thromb. Vasc. Biol. 15 5 1995 551 561
2. K.J. Moore, and I. Tabas Macrophages in the pathogenesis of atherosclerosis Cell 145 3 2011 341 355
3. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, and et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 9493 2005 1267 1278
4. Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults Chinese guidelines on prevention and treatment of dyslipidemia in adults Chin. J. Cardiol. 05 2007 390 419
5. P.S. Jellinger, D.A. Smith, A.E. Mehta, O. Ganda, Y. Handelsman, H.W. Rodbard, and et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis Endocr. Pract. 18 Suppl. 1 2012 1 78
6. Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, and et al. ESC/EAS Guidelines for the management of dyslipidaemias Rev. Esp. Cardiol. 64 12 2011 (1168.e1-.e60)
7. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Merz, C.B. Blum, R.H. Eckel, and et al. ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2013 2013
8. F.J. Raal, D.J. Blom, S. Naidoo, P. Bramlage, and P. Brudi Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS) Cardiovasc. J. Afr. 24 8 2013 330 338
9. D. Devroey, R.P. Radermecker, Van der Schueren BJ, B. Torbeyns, and R.J. Jaken Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) Int. J. Clin. Pract. 68 2 2014 180 187
10. S.N. Al Sifri, W. Almahmeed, S. Azar, O. Okkeh, P. Bramlage, C. Junger, and et al. Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment PLoS One 9 1 2014 e84350
11. G. Yang, Y. Wang, Y. Zeng, G.F. Gao, X. Liang, M. Zhou, and et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010 Lancet 381 9882 2013 1987 2015
12. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N. Engl. J. Med. 339 4 1998 229 234
13. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2 2000 207 213
14. W.C. Roberts The rule of 5 and the rule of 7 in lipid-lowering by statin drugs Am. J. Cardiol. 80 1 1997 106 107
15. L. Ryden, P.J. Grant, S.D. Anker, C. Berne, F. Cosentino, N. Danchin, and et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Eur. Heart J. 34 39 2013 3035 3087
16. F.B. Hu, and W.C. Willett Optimal diets for prevention of coronary heart disease JAMA 288 20 2002 2569 2578
17. R.J. Achttien, J.B. Staal, S. van der Voort, H.M. Kemps, H. Koers, M.W. Jongert, and et al. Exercise-based cardiac rehabilitation in patients with coronary heart disease: a practice guideline Neth. Heart J. 21 10 2013 429 438
18. H. Naci, and J.P. Ioannidis Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study BMJ 347 2013 f5577
19. R. Collins, R. Peto, S. MacMahon, P. Hebert, N.H. Fiebach, K.A. Eberlein, and et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context Lancet 335 8693 1990 827 838
20. Y. Chen, W.K. Copeland, R. Vedanthan, E. Grant, J.E. Lee, D. Gu, and et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium BMJ 347 2013 f5446
21. S.B. Hachem, and A.D. Mooradian Familial dyslipidaemias: an overview of genetics, pathophysiology and management Drugs 66 15 2006 1949 1969
22. J.M. Chehade, M. Gladysz, and A.D. Mooradian Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management Drugs 73 4 2013 327 339
23. A.K. Gitt, H. Drexel, J. Feely, J. Ferrieres, J.R. Gonzalez-Juanatey, K.K. Thomsen, and et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada Eur. J. Prev. Cardiol. 19 2 2012 221 230
24. W.S. Summerskill, and C. Pope 'I saw the panic rise in her eyes, and evidence-based medicine went out of the door'. An exploratory qualitative study of the barriers to secondary prevention in the management of coronary heart disease Fam. Pract. 19 6 2002 605 610
25. M. Lemstra, D. Blackburn, A. Crawley, and R. Fung Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis Can. J. Cardiol. 28 5 2012 574 580
26. Z. Reiner, Z. Sonicki, and E. Tedeschi-Reiner Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey Prev. Med. 51 6 2010 494 496
27. Z. Reiner, Z. Sonicki, and E. Tedeschi-Reiner Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey Atherosclerosis 213 2 2010 598 603
28. A.-H. Investigators, W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N. Engl. J. Med. 365 24 2011 2255 2267
29. H.-T.C. Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur. Heart J. 34 17 2013 1279 1291
30. M.J. Chapman Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives Atherosclerosis 171 1 2003 1 13
31. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, P. Linz, and et al. Effects of combination lipid therapy in type 2 diabetes mellitus N. Engl. J. Med. 362 17 2010 1563 1574
32. D. Morrone, W.S. Weintraub, P.P. Toth, M.E. Hanson, R.S. Lowe, J. Lin, and et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials Atherosclerosis 223 2 2012 251 261
33. A.E. Pesaro, C.V. Serrano Jr., J.L. Fernandes, A.B. Cavalcanti, A.H. Campos, H.S. Martins, and et al. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin Int. J. Cardiol. 158 3 2012 400 404
34. K.A. Gudzune, A.K. Monroe, R. Sharma, P.D. Ranasinghe, Y. Chelladurai, and K.A. Robinson Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review Ann. Intern. Med. 160 7 2014 468 476
35. S. Rabar, M. Harker, N. O'Flynn, and A.S. Wierzbicki Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance BMJ 349 2014 g4356